Table 3.
Training cohort and validation cohort baseline characteristics
| Characteristics | Entire cohort N = 229 |
Training cohort N1 = 129 |
Validation cohort N2 = 100 |
P value |
|---|---|---|---|---|
| Gender | 0.062 | |||
| Male | 145 (63.3) | 81 (62.8) | 64 (64.0) | |
| Female | 84 (36.7) | 48 (37.2) | 36 (36.0) | |
| Age (years) | 60.42 ± 7.17 | 60.12 ± 8.99 | 59.38 ± 10.19 | 0.728 |
| < 60 | 103 (45.0) | 59 (45.7) | 44 (44.2) | |
| ≥ 60 | 126 (55.0) | 70 (54.3) | 56 (55.8) | |
| Smoking or drinking | 0.324 | |||
| Yes | 120 (52.4) | 68 (52.7) | 52 (52.3) | |
| No | 109 (47.6) | 61 (47.3) | 48 (47.7) | |
| Tumor location | 0.134 | |||
| ICC | 109 (47.6) | 61 (47.3) | 48 (47.6) | |
| HCCA | 45 (19.7) | 25 (19.8) | 20 (19.8) | |
| DCCA | 32 (14.0) | 18 (13.1) | 14 (14.0) | |
| GCA | 43 (18.7) | 25 (19.8) | 18 (18.6) | |
| Tumor differentiation | 0.224 | |||
| Well | 13 (5.7) | 7 (5.4) | 6 (5.8) | |
| Moderately | 67 (29.3) | 37 (28.7) | 30 (30.2) | |
| Poorly | 65 (28.4) | 36 (27.9) | 29 (29.1) | |
| Unknown | 84 (36.6) | 49 (38.0) | 35 (34.9) | |
| Serum albumin | 0.336 | |||
| < 36 g/L | 137 (59.8) | 77 (59.7) | 60 (60.5) | |
| ≥ 36 g/L | 92 (40.2) | 52 (40.3) | 40 (39.5) | |
| Liver metastasis | 0.205 | |||
| Yes | 139 (60.7) | 81 (62.8) | 58 (58.1) | |
| No | 90 (39.3) | 48 (37.2) | 42 (41.9) | |
| Multi-site metastasis | 0.084 | |||
| Yes | 130 (56.8) | 77 (59.7) | 53 (53.5) | |
| No | 99 (43.2) | 52 (40.3) | 47 (46.5) | |
| Types of immune drugs | 0.718 | |||
| Camrelizumab | 49 (21.3) | 28 (21.7) | 21 (20.9) | |
| Pembrolizumab | 51 (22.3) | 30 (23.3) | 21 (20.9) | |
| Toripalimab | 62 (20.1) | 36 (27.9) | 26 (25.6) | |
| Others | 67 (29.3) | 35 (27.1) | 32 (32.6) | |
| Response | 0.077 | |||
| CR | 18 (7.9) | 10 (7.8) | 8 (8.1) | |
| PR | 75 (32.8) | 41 (31.8) | 34 (33.7) | |
| SD | 111 (48.5) | 65 (50.4) | 46 (46.5) | |
| PD | 25 (10.8) | 13 (10.0) | 12 (11.7) | |
| NLR | 0.321 | |||
| < 3.0 | 100 (43.7) | 57 (44.2) | 43 (43.0) | |
| ≥ 3.0 | 129 (56.3) | 72 (55.8) | 57 (57.0) | |
| PLR | 0.068 | |||
| < 160 | 99 (43.2) | 58 (45.0) | 41 (40.7) | |
| ≥ 160 | 130 (56.8) | 71 (55.0) | 59 (59.3) | |
| Total bilirubin | 0.144 | |||
| < 21umol/L | 60 (26.2) | 34 (26.4) | 26 (25.6) | |
| ≥ 21umol/L | 169 (73.8) | 95 (73.6) | 74 (74.4) | |
| ALT | 0.101 | |||
| < 50U/mL | 109 (47.6) | 61 (47.3) | 48 (47.6) | |
| ≥ 50U/mL | 120 (52.4) | 68 (52.7) | 52 (52.4) | |
| CA19-9 | 0.331 | |||
| < 37U/mL | 84 (36.7) | 42 (32.6) | 42 (42.6) | |
| ≥ 37U/mL | 145 (63.3) | 87 (67.4) | 58 (58.1) | |
| AST | 0.057 | |||
| < 40U/mL | 83 (36.2) | 48 (37.2) | 35 (34.9) | |
| ≥ 40U/mL | 146 (63.8) | 81 (62.8) | 65 (65.1) | |
| MLR | 0.237 | |||
| < 2.3 | 108 (47.2) | 60 (46.5) | 48 (47.6) | |
| ≥ 2.3 | 121 (52.8) | 69 (53.5) | 52 (52.4) | |
| SII | 0.054 | |||
| < 830.06 | 103 (45.0) | 58 (45.0) | 45 (45.3) | |
| ≥ 830.06 | 126 (55.0) | 71 (55.0) | 55 (54.7) | |
| CONUT score | 0.104 | |||
| < 2 | 101 (44.1) | 59 (45.7) | 42 (41.9) | |
| ≥ 2 | 128 (55.9) | 70 (54.3) | 58 (58.1) |